FGFR3 and urinary bladder carcinoma: At present, FDA has approved several FGFR inhibitors for the clinical treatment of cancer.204,205 In addition, the use of antibodies that actively bind to the FGFR3 antigen can not only achieve therapeutic effects, but also effectively target bladder cancer cells.